New Pharmaceuticals market report from Current Partnering: "Age-related Macular Degeneration Partnering 2007-2013"
Boston, MA -- (SBWIRE) -- 10/04/2013 -- Age-related Macular Degeneration Partnering 2007-2013 report provides understanding and access to the age-related macular degeneration partnering deals and agreements entered into by the worlds leading healthcare companies.
- Trends in age-related macular degeneration partnering deals
- Top age-related macular degeneration deals by value
- Deals listed by company A-Z, industry sector, stage of development, technology type
Age-related Macular Degeneration Partnering 2007-2013 provides understanding and access to the age-related macular degeneration partnering deals and agreements entered into by the worlds leading healthcare companies.
View Full Report Details and Table of Contents
The report provides an analysis of age-related macular degeneration partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors age-related macular degeneration technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.
This data driven report contains over 70 links to online copies of actual liver disease deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
The initial chapters of this report provide an orientation of HIV partnering trends.
Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in age-related macular degeneration partnering since 2007, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.
Chapter 3 provides an overview of the leading age-related macular degeneration deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- Macular Degeneration - Pipeline Review, H1 2013
- Macular Degeneration - Pipeline Review, H2 2013
- Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2013
- Age Related Macular Degeneration - Pipeline Review, H1 2013
- Dry (Atrophic) Macular Degeneration - Pipeline Review, H1 2013
- Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H2 2012
- Ophthalmology Therapeutics Market to 2018 - Dosing Convenience and Cost-effectiveness Continue to Drive Eylea's Prescription Share in Wet Age-Related Macular Degeneration (Wet-AMD)
- Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H1 2013
- Cystoid Macular Edema Global Clinical Trials Review, H2, 2012
- Advanced Cell Technology, Inc. (ACTC) - Financial and Strategic SWOT Analysis Review
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)